Rotman Research Institute at Baycrest
Toronto, Ontario, M6A 2E1, Canada
Location status: Recruiting
NCT Number: NCT07212465
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have not tolerated or responded to antidepressant medications. The study will evaluate whether accelerated dTMS administered over 5 consecutive days is safe and well-tolerated in this population, and whether it produces greater reductions in depressive symptoms compared to placebo stimulation.
Interested in participating?
Request Info60 year–85 year
All sexes
Interventional
Not applicable
Toronto, Ontario, M6A 2E1, Canada
Location status: Recruiting
This study will investigate the effects of an accelerated intermittent theta burst protocol (a-iTBS) using the H7 deep Transcranial Magnetic Stimulation (dTMS) coil to target the anterior cingulate cortex (ACC) in older adults (aged 60-85) with Major Depressive Disorder (MDD). Twenty-four older adults with treatment-resistant MDD will participate in a single site, double-blind, randomized sham-controlled trial using an accelerated schedule of multiple dTMS sessions per day for 5 consecutive days. The primary goal of the study is to establish the feasibility of an accelerated aiTBS protocol of the ACC in older adults with treatment resistant depression, and to obtain preliminary evidence of treatment efficacy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.
In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.
Time frame: 6 weeks
Time frame: 6 weeks
Severity of symptoms is rated from 1 to 4, with 1 being absent and 4 being severe. Whether symptoms are perceived to be relatedTMS treatment are rated from 1 to 5, with 1 being no and 5 being definitely.
Time frame: 6 weeks
Time frame: 1 week
An effect size (Cohen's d) of 0.5 will be considered a minimally important effective size. The MADRS ranges from 0-60, with a greater score indicating greater depressive symptoms.
Time frame: 6 weeks
Response rates will be compared from baseline to after 5 day treatment and at 1 month follow-up. MADRS scores range from 0-60, with a greater score indicating greater severity of depressive symptoms.
Time frame: 6 weeks
MADRS scores will be compared between baseline, after 5 days of treatment and at 1-month follow-up. The MADRS ranges from 0-60, with a greater score indicating greater depressive symptoms
Time frame: 6 weeks
Time frame: 1 week
Time frame: 1 week
Time frame: 6 weeks
Baseline cognitive tests will be measured using a neuropsychological test battery.
Time frame: 1 week
Time frame: 6 weeks
The Affective Simon task will measure the number of correct responses to stimuli in the task.
Contact information is provided by the study sponsor or research team.
Rotman Research Institute at Baycrest
Other
Feasibility, Tolerability, and Preliminary Efficacy for Non-Invasive Neuromodulation of the Anterior Cingulate Cortex for Depression (NACC-D) in Older Adults Using Deep Transcranial Magnetic Stimulation With an Accelerated Intermittent Theta Burst Protocol
Acronym: NACC-D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07284667
Depressive Disorder, Depressive Disorder, Major
Birmingham, Alabama, United States
View Trial DetailsNCT07696871
Depressive Disorder, Depressive Disorder, Major
Tubarão, Santa Catarina, Brazil
View Trial DetailsNCT07603804
Behavior, Behavioral Symptoms
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07217223
Depressive Disorder, Depressive Disorder, Major
San Diego, California, United States
View Trial Details